169 related articles for article (PubMed ID: 32169919)
41. Radiolabeled anti-CD45 monoclonal antibodies target lymphohematopoietic tissue in the macaque.
Matthews DC; Appelbaum FR; Eary JF; Hui TE; Fisher DR; Martin PJ; Durack LD; Nelp WB; Press OW; Badger CC
Blood; 1991 Oct; 78(7):1864-74. PubMed ID: 1832994
[TBL] [Abstract][Full Text] [Related]
42. Biodistribution and Radiation Dosimetry of Intraperitoneally Administered
Grkovski M; Modak S; Zanzonico PB; Carrasquillo JA; Larson SM; Humm JL; Pandit-Taskar N
J Nucl Med; 2022 Jul; 63(7):1094-1100. PubMed ID: 34857661
[TBL] [Abstract][Full Text] [Related]
43. A comparison of the biodistribution and biokinetics of (99m)Tc-anti-CD66 mAb BW 250/183 and (99m)Tc-anti-CD45 mAb YTH 24.5 with regard to suitability for myeloablative radioimmunotherapy.
Buchmann I; Kull T; Glatting G; Bunjes D; Hale G; Kotzerke J; Rattat D; Dohner H; Reske SN
Eur J Nucl Med Mol Imaging; 2003 May; 30(5):667-73. PubMed ID: 12599012
[TBL] [Abstract][Full Text] [Related]
44. Dosimetry of 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial.
Delaloye AB; Antonescu C; Louton T; Kuhlmann J; Hagenbeek A
J Nucl Med; 2009 Nov; 50(11):1837-43. PubMed ID: 19837764
[TBL] [Abstract][Full Text] [Related]
45. PET-based radiation dosimetry in man of 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer.
Zanzonico PB; Finn R; Pentlow KS; Erdi Y; Beattie B; Akhurst T; Squire O; Morris M; Scher H; McCarthy T; Welch M; Larson SM; Humm JL
J Nucl Med; 2004 Nov; 45(11):1966-71. PubMed ID: 15534070
[TBL] [Abstract][Full Text] [Related]
46. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.
Shen S; Forero A; LoBuglio AF; Breitz H; Khazaeli MB; Fisher DR; Wang W; Meredith RF
J Nucl Med; 2005 Apr; 46(4):642-51. PubMed ID: 15809487
[TBL] [Abstract][Full Text] [Related]
47. Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities.
Buchmann I; Bunjes D; Kotzerke J; Martin H; Glatting G; Seitz U; Rattat D; Buck A; Döhner H; Reske SN
Cancer Biother Radiopharm; 2002 Apr; 17(2):151-63. PubMed ID: 12030109
[TBL] [Abstract][Full Text] [Related]
48. Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients.
Rousseau C; Ferrer L; Supiot S; Bardiès M; Davodeau F; Faivre-Chauvet A; Baumgartner P; Wijdenes J; Lacombe M; Barbet J; Guillaume T; Moreau P; Harousseau JL; Kraeber-Bodéré F; Cherel M
Tumour Biol; 2012 Jun; 33(3):679-88. PubMed ID: 22389160
[TBL] [Abstract][Full Text] [Related]
49. 3D absorbed dose distribution estimated by Monte Carlo simulation in radionuclide therapy with a monoclonal antibody targeting synovial sarcoma.
Sarrut D; Badel JN; Halty A; Garin G; Perol D; Cassier P; Blay JY; Kryza D; Giraudet AL
EJNMMI Phys; 2017 Dec; 4(1):6. PubMed ID: 28101733
[TBL] [Abstract][Full Text] [Related]
50. Dosimetry in myeloablative (90)Y-labeled ibritumomab tiuxetan therapy: possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary results.
Chiesa C; Botta F; Di Betta E; Coliva A; Maccauro M; Aliberti G; Bavusi S; Devizzi L; Guidetti A; Seregni E; Gianni AM; Bombardieri E
Cancer Biother Radiopharm; 2007 Feb; 22(1):113-20. PubMed ID: 17627419
[TBL] [Abstract][Full Text] [Related]
51. Clinical Internal Dosimetry and Biodistribution of 177 Lu-DOTA-Trastuzumab in HER2-Positive Metastatic and Locally Advanced Breast Carcinoma.
Narwadkar YS; Parghane RV; Sahu S; Lad S; Deep K; Wanage G; Suralkar T; Banerjee S; Gupta S; Basu S; Badwe RA
Clin Nucl Med; 2024 Apr; 49(4):e149-e155. PubMed ID: 38350067
[TBL] [Abstract][Full Text] [Related]
52. Dosimetry Assessment of Injected 89Zr-Labeled Monoclonal Antibodies in Humans.
Zakaly HMH; Mostafa MYA; Zhukovsky M
Radiat Res; 2019 May; 191(5):466-474. PubMed ID: 30896281
[TBL] [Abstract][Full Text] [Related]
53. (99m)Tc-labeled murine ior C5 monoclonal antibody in colorectal carcinoma patients: pharmacokinetics, biodistribution, absorbed radiation doses to normal organs and tissues and tumor localization.
Iznaga-Escobar N; Ramos-Suzarte M; Morales-Morales A; Torres-Arocha L; Rodríguez-Mesa N; Pérez-Rodriguez R
Methods Find Exp Clin Pharmacol; 2004 Nov; 26(9):687-96. PubMed ID: 15632954
[TBL] [Abstract][Full Text] [Related]
54. Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer.
Juweid M; Sharkey RM; Swayne LC; Griffiths GL; Dunn R; Goldenberg DM
J Nucl Med; 1998 Jan; 39(1):34-42. PubMed ID: 9443735
[TBL] [Abstract][Full Text] [Related]
55. Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin.
Breitz HB; Fisher DR; Goris ML; Knox S; Ratliff B; Murtha AD; Weiden PL
Cancer Biother Radiopharm; 1999 Oct; 14(5):381-95. PubMed ID: 10850323
[TBL] [Abstract][Full Text] [Related]
56. Correlation of marrow dose estimates based on serial pretreatment radiopharmaceutical imaging and blood data with actual marrow toxicity in anti-CD20 yttrium-90 monoclonal antibody radioimmunotherapy of non-Hodgkin's B-cell lymphoma.
Erwin WD; Spies SM; Kelly ME; Rao P; Eckersberg-Rhodes TE; Nannapaneni M; Groch MW
Nucl Med Commun; 2001 Feb; 22(2):247-55. PubMed ID: 11258413
[TBL] [Abstract][Full Text] [Related]
57. Clinical Translation and First In-Human Use of [
Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
[TBL] [Abstract][Full Text] [Related]
58. High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial.
Tempero M; Leichner P; Baranowska-Kortylewicz J; Harrison K; Augustine S; Schlom J; Anderson J; Wisecarver J; Colcher D
Clin Cancer Res; 2000 Aug; 6(8):3095-102. PubMed ID: 10955789
[TBL] [Abstract][Full Text] [Related]
59. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA
J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
[TBL] [Abstract][Full Text] [Related]
60. A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer.
Sharkey RM; Hajjar G; Yeldell D; Brenner A; Burton J; Rubin A; Goldenberg DM
J Nucl Med; 2005 Apr; 46(4):620-33. PubMed ID: 15809485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]